RadNet (RDNT) Raised Guidance, Is The Stock Still A Bargain?
Why RadNet Stock Is In Focus After Its Latest Earnings Report
RadNet (RDNT) recently reported second quarter results that included a 25.0% revenue increase and higher full year revenue and adjusted EBITDA guidance, putting the stock on many investors' radar.
At a share price of US$73.71, RadNet has seen strong recent momentum, with a 30 day share price return of 9.92% and a 90 day share price return of 35.65%, while longer term total shareholder returns over three and five years have also been very strong.
Scan for other healthcare and AI imaging stocks showing similar momentum by reviewing the hand picked 37 healthcare AI stocks alongside RadNet after this earnings update.
After RadNet's strong run and higher guidance, some investors may feel pressure to act quickly. Others will wonder if recent gains already reflect the good news and prefer to wait. The valuation numbers help frame that choice.
Most Popular Narrative: 20.6% Undervalued
Compared with RadNet's last close at $73.71, the most widely followed narrative sees fair value at $92.88, which frames the recent share price strength in a different light.
The nationwide aging demographic and growth in chronic disease-related imaging (cancer, Alzheimer's, cardiac) is steadily driving up demand and volumes for advanced diagnostic procedures (e.g., PET/CT, cardiac CT). This is supporting sustained top-line revenue growth and utilization rates across RadNet's expanding center network.
Want to understand why this framework supports a higher value for RadNet? The narrative leans on sustained revenue expansion, rising profitability, and a richer future earnings multiple. Curious which specific growth and margin assumptions sit underneath that headline fair value and how they link back to forecast earnings power?
Result: Fair Value of $92.88 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, RadNet still faces real execution tests, including the cash demands of ongoing AI investments and the chance that reimbursement terms or imaging volumes fall short of current expectations.
Find out about the key risks to this RadNet narrative.
Another View On RadNet's Valuation
While the first framework points to RadNet trading below fair value, the P/S ratio tells a different story. The stock trades on a 2.6x P/S, which is higher than the US Healthcare industry at 1.5x and above a fair ratio of 1.1x, so investors face a clear valuation trade off.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
With RadNet attracting both optimism and caution in this article, now is a good time to review the details for yourself and form your own stance using the 3 key rewards and 2 important warning signs.
Looking For More Investment Ideas Beyond RadNet?
If you stop with RadNet, you could miss other stocks that fit your style. Use the Simply Wall Street Screener to widen your opportunity set with focus.
- Target potential value opportunities by running the 47 high quality undervalued stocks and see which companies line up with your preferred balance of quality and price.
- Prioritize resilience and sleep easier at night by reviewing the 82 resilient stocks with low risk scores that flags stocks with relatively lower risk scores.
- Spot companies that the market may be overlooking by checking the 19 high quality undiscovered gems before attention and liquidity potentially increase.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com